Abstract 3073
Background
Management of Ca treatment-related symptoms is an important safety issue. The value of nursing in symptom management is critical and becoming increasingly so as the treatment becomes more remarkably complex.
Methods
Qualitative research Descriptive case study Describe the problems of a 28year old dx with Hodgkin’s Disease.
Results
Chemotherapy Day Hospital (CDH) was the 1st contact with the oncology reality Focus: familiarization with a hostil atmosphere develop links between patient-nurses change of routines impact on ADL management of CT’s effects therapeutic regimen increase one’s resilience and hope while in treatment reduce long-term complications of the Ca tips to promote comfort: minimize suffering assisting patient navigation in the care continuum Relapse after 6 months New CT treatment (inpatient setting) Anxiety attacks due to the adaptation/awareness of his new condition Focus: management of bad news and CT’s side effects requested collaboration to the nurse of the CDH in the adaptation of strategies of adhesion to the new CT/hospitalization hospital routines adapted to his habits self care promotion psychological support articulation between services communication among nurses - promote the continuity of care New relapse Began immunotherapy: hospitalized after pulmonar toxicity In this scope he performed a bronchoscopy No curative therapy indication Due to tiredness/dyspnea a personalized respiratory rehabilitation plan was developed by a nurse: breathing optimization energy conservation techniques teaching positions of rest/relaxation In the end-of-life were adopted non-pharmacological strategies: relief of dyspnea (guidelines of the nurse of the bronchoscopy unit) positioning massage distraction techniques his mother was allowed to spend the night with him D/C was possible to fulfill one of his desires After a month he was admitted (neurological changes) and passed away.
Conclusions
During the treatment period of the disease the patient went through 3 distinctive services where it was necessary to have an individualized/specialized approach as well as an articulation/communication among the nurses in order to guarantee an effectively management of symptoms and the quality/safety of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract